Company intelligence / Profile preview

BluMaiden Biosciences

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

BluMaiden Biosciences leverages proprietary AI-driven platforms to mine human genomic and microbiomic data for novel small molecule therapeutics. Its lead programs target inflammatory diseases at the preclinical stage. The company’s service arm delivers actionable clinical insights supporting decision-making in pharma-sponsored trials across all phases. No published late-stage or commercial results yet.

Therapeutic areas: OtherImmunology
Modalities: Small molecules (human-derived, microbiome-derived)Biomarkers (microbiome-based)
Industry: Biotech

Partnerships

AWS Advanced Technology Partner & AWS Competency Partner; partnerships with healthcare/life science companies in US & Europe.

Beyond the preview

Go deeper on BluMaiden Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BluMaiden Biosciences.

Explore the full profile